CompletedPhase 1NCT00003081
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Jean E. Sanders, MDFred Hutchinson Cancer Center
- Intervention
- filgrastim(biological)
- Enrollment
- 16 enrolled
- Eligibility
- 49 years · All sexes
- Timeline
- 1998 – 2002
Study locations (1)
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003081 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07054944Tumor-Lymph Node MappingUniversity of Rochester
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC